Intas Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

The pharma industry registered a 7.5% value growth year-on-year for the month of February, with sales of ₹18,781 crore, ...

Telangana: Natco Pharma has appointed Bhimrao Dattu Jadhav as Senior Vice President - Operations (Formulations) for Pharma ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...

The National Pharmaceutical Pricing Authority (NPPA) has notified the retail price of 53 new drugs based on applications submitted by individual companies, after finalising the same in the latest ...

Other unlisted companies that have been placed in the top 10 in the report in terms of valuation are Megha Engineering & Infrastructures, Parle Products, Intas Pharmaceuticals, Dream11 ...

Among them, the cardiac, gastrointestinal, and antidiabetic therapies saw high value growth of 9.5 per cent, 9.6 per cent, ...

Over the years, the broader pharmaceutical space has witnessed considerable interest from both strategic and institutional investors. For instance, Gujarat-based drugmaker Intas Pharmaceuticals Ltd, ...

Parle is valued at Rs 68,640 crore, under the leadership of CEO Vijay Kantilal Chauhan. 7. Intas Pharma has a valuation of Rs 68,150 crore, with Nimish Chudgar serving as its CEO. 8. Dream11's ...

In the group of unlisted companies within the top 10, Intas Pharmaceuticals and Dream11 experienced minor value growths of 10% and 13%, respectively. Meanwhile, Razorpay, the foremost payments ...